Aileron Therapeutics Showcases Promising LTI-03 Results for Idiopathic Pulmonary Fibrosis at ICLAF

Aileron Therapeutics,  a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...

October 14, 2024 | Monday | News
Pfizer Receives FDA Approval for HYMPAVZI™: A New Treatment for Hemophilia A and B

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis ...

October 14, 2024 | Monday | News
Burning Rock and Dizal Announce First NGS-Based Lung Cancer Diagnostic Approval by China’s NMPA

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision onco...

October 11, 2024 | Friday | News
RoukenBio Launches New Brand Identity and Completes Phase 2 Expansion of Discovery Centre in Scotland

  RoukenBio, the Collaborative Research Organisation (CRO) formerly known as Antibody Analytics, has today announced completion of the phase 2 expans...

October 04, 2024 | Friday | News
Oncocyte's GraftAssure™ Assay Adopted by Top U.S. and German Transplant Hospitals, Progresses Toward FDA Submission

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume Company clears first stage...

October 03, 2024 | Thursday | News
Citryll Launches Pioneering Collaboration with Dutch Rheumatology Experts to Advance NET-Targeting Therapies for Rheumatoid Arthritis

Learnings will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013 ...

October 03, 2024 | Thursday | News
Kailera Therapeutics Launches with Ambitious Plans for GLP-1 Drugs Targeting Obesity and Metabolic Conditions

In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...

October 02, 2024 | Wednesday | News
LeaderMed and Combiphar Form Joint Venture to Launch Phase 3 Trial of Novel Diabetes Treatment in Indonesia

LeaderMed Group (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast Asia, ann...

October 01, 2024 | Tuesday | News
SIFI Secures European Patent for Innovative Polihexanide Formulation in Germany Eye Infection Treatment

The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fung...

September 30, 2024 | Monday | News
Phase 3 CEPHEUS Study Shows 60.9% MRD-Negativity Rate and 43% Reduction in Risk of Progression or Death in Multiple Myeloma

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase ...

September 30, 2024 | Monday | News
Enliven Therapeutics Reports Promising 44% MMR Rate at 24 Weeks in Phase 1 CML Trial for ELVN-001

Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...

September 30, 2024 | Monday | News
Emmes Secures Major NIH Contract to Lead Clinical Coordinating Center for National Institute on Drug Abuse Trials

Emmes, part of Emmes Group, announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials &nbs...

September 26, 2024 | Thursday | News
Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Lupus Nephritis, Demonstrating Superiority Over Standard Therapy Alone

Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...

September 26, 2024 | Thursday | News
European Commission Approves Junshi Biosciences' Toripalimab for Two Key Cancer Indications

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

September 25, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close